ABEONasdaqPharmaceutical PreparationsFiscal year ends December 31
ABEONA THERAPEUTICS INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$4.41−0.02 (-0.45%)
Close on Oct 19, 2026
- Market cap
- $251.58M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
73.7%
Operating margin
-1536.9%−722.7 pts over 5 years
Net margin
1223.1%+2065.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | – | +60.3% | -10.3% | +18.8% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -26.2% | -60.0% | 70.0% | |
| Return on assets | -22.9% | -45.0% | 43.3% | |
| Current ratio | 8.37 | 2.33 | 6.93 | |
| Debt to equity | – | – | 0.13 | |
| Net debt to EBITDA | – | – | 0.67× | |
| Interest coverage | – | -19.8× | -23.9× | |
| Capex to revenue | 58.4% | 13.4% | 137.0% | |
| Diluted shares | 1M | 4M | 66M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Abeona Therapeutics generated $278.50M from operations and spent $15.03M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$278.50M
Used
$15.03M
Capital expenditure$15.03M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin1223.1%
×Asset turnover0.04×
×Equity multiplier1.62×
=Return on equity, FY202570.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 1223.1% | 0.04× | 1.62× | 70.0% |
| FY2023 | -1548.2% | 0.05× | 3.08× | -260.6% |
| FY2022 | -2807.4% | 0.02× | 2.08× | -114.8% |
| FY2021 | -2831.2% | 0.03× | 1.59× | -117.2% |
| FY2020 | -842.3% | 0.05× | 1.33× | -60.0% |
| FY2018 | -1890.3% | 0.02× | 1.16× | -37.3% |
| FY2017 | -3263.9% | 0.01× | 1.08× | -20.3% |
| FY2016 | -2460.4% | 0.01× | 1.15× | -26.2% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero$71.18M
- Cash generatingOperating cash flow above zero-$76.33M
- Return on assets improvedROA up on the prior year-99.6% → 65.3%
- Earnings backed by cashOperating cash flow above net income-$76.33M vs $71.18M
- Less leverageLong-term debt to assets fell12.0% → 3.6%
- Better liquidityCurrent ratio rose6.08 → 6.93
- No dilutionShare count did not rise41M → 66M
- Gross margin improvedGross margin up on the prior year– → 73.68%
- More efficientAsset turnover rose– → 0.05